Correlation Between Amicus Therapeutics and Avadel Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Avadel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Avadel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amicus Therapeutics and Avadel Pharmaceuticals PLC, you can compare the effects of market volatilities on Amicus Therapeutics and Avadel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Avadel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Avadel Pharmaceuticals.

Diversification Opportunities for Amicus Therapeutics and Avadel Pharmaceuticals

0.72
  Correlation Coefficient

Poor diversification

The 3 months correlation between Amicus and Avadel is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Avadel Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Avadel Pharmaceuticals and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Avadel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Avadel Pharmaceuticals has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Avadel Pharmaceuticals go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Avadel Pharmaceuticals

Given the investment horizon of 90 days Amicus Therapeutics is expected to generate 0.54 times more return on investment than Avadel Pharmaceuticals. However, Amicus Therapeutics is 1.87 times less risky than Avadel Pharmaceuticals. It trades about -0.1 of its potential returns per unit of risk. Avadel Pharmaceuticals PLC is currently generating about -0.11 per unit of risk. If you would invest  1,169  in Amicus Therapeutics on September 5, 2024 and sell it today you would lose (190.00) from holding Amicus Therapeutics or give up 16.25% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Amicus Therapeutics  vs.  Avadel Pharmaceuticals PLC

 Performance 
       Timeline  
Amicus Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Avadel Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Avadel Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Amicus Therapeutics and Avadel Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Amicus Therapeutics and Avadel Pharmaceuticals

The main advantage of trading using opposite Amicus Therapeutics and Avadel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Avadel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avadel Pharmaceuticals will offset losses from the drop in Avadel Pharmaceuticals' long position.
The idea behind Amicus Therapeutics and Avadel Pharmaceuticals PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation